MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Agios Pharmaceuticals Net Debt 2011-2026 | AGIO
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Agios Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -48.9 M | -19.3 M | -16.2 M | -53.6 M | -192 M | -127 M | 32.7 M | -70.5 M | -103 M | -161 M | -71.8 M | -14 M | -71.6 M | -91.3 M | -118 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 32.7 M | -192 M | -75 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
Nanobiotix S.A.
NBTX
|
-80 M | $ 30.34 | -0.82 % | $ 286 B |  France |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M |  USA |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | France |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
-973 M | $ 95.5 | 3.83 % | $ 27.2 B | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 2.92 | -0.34 % | $ 6.35 B |  Israel |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 20.37 | -2.4 % | $ 952 M | USA |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | USA |
 |
Celldex Therapeutics
CLDX
|
-26.5 M | $ 32.24 | -4.1 % | $ 2.14 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-133 M | $ 1.4 | -0.71 % | $ 360 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.08 | -2.16 % | $ 436 M | USA |
 |
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 24.21 | -1.47 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.49 | 1.36 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
-188 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-19.9 M | $ 2.55 | -0.78 % | $ 16 M | USA |
 |
InflaRx N.V.
IFRX
|
-32.3 M | $ 1.0 | -2.91 % | $ 152 M | Germany |
 |
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | Britain |
 |
Immutep Limited
IMMP
|
-17.4 M | $ 0.31 | -2.52 % | $ 1.08 B |  Australia |
 |
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-5.45 M | $ 3.83 | -2.3 % | $ 258 B | Britain |
 |
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | USA |
 |
Evogene Ltd.
EVGN
|
-3.44 M | $ 0.81 | -1.16 % | $ 27.9 M | Israel |
 |
Baudax Bio
BXRX
|
1.86 M | - | 0.59 % | $ 63 K | USA |
 |
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | USA |
 |
Cabaletta Bio
CABA
|
-76.6 M | $ 3.13 | -1.26 % | $ 315 M | USA |